Short-Term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis: A prospective 12-month follow-up study

Inflammatory Bowel Diseases

Volumn 19, Issue 11, 2013, Pages 2380-2386

  Langhorst, Jost ^a   Hofstetter, Anna ^a   Wolfe, Fred ^b,c   Häuser, Winfried ^d,e  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^d KLINIKUM SAARBRÜCKEN   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Depression; Mucosal healing; Relapse; Stress; Ulcerative colitis

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; COHEN PERCEIVED STRESS SCALE; CONFIDENCE INTERVAL; DEPRESSION; ENDOSCOPY; FEMALE; FOLLOW UP; GENDER; HAZARD RATIO; HISTOLOGY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA; PERCEIVE STRESS QUESTIONNAIRE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; QUESTIONNAIRE; RELAPSE; REMISSION; RISK; STRESS; ULCER HEALING; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; DEPRESSION; ENDOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; STRESS, PHYSIOLOGICAL; TIME FACTORS; WOUND HEALING;

EID: 84888238341     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182a192ba     Document Type: Article

References (47)

1. Sainsbury A, Heatley RV. Review article: psychosocial factors in the quality of life of patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;21:499-508.
2. Prenzler A, Bokemeyer B, Mittendorf T, et al. Costs of ulcerative colitis within the German Statutory Health Insurance [Article in German]. Dtsch Med Wochenschr. 2010;135:281-286.
3. Colombel JF, Watson AJ, Neurath MF. The 10 remaining mysteries of inflammatory bowel disease. Gut. 2008;57:429-433.
4. Bernstein CN, Singh S, Graff LA, et al. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol. 2010; 105:1994-2002.
5. Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in German patients with Inflammatory bowel disease: results from a national survey. Inflamm Bowel Dis. 2005;3:287-295.
6. Drossman DA. Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosom Med. 1998;60:258-267.
7. Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: A review of comorbidity and management. Inflamm Bowel Dis. 2009;15:1105-1118.
8. Maunder RG, Levenstein S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. Curr Mol Med. 2008;8:247-252.
9. Cámara RJ, Ziegler R, Begré S, et al; Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) group. The role of psychological stress in inflammatory bowel disease: quality assessment of methods of 18 prospective studies and suggestions for future research. Digestion. 2009;80:129-139.
10. Kane S, Lu F, Kornbluth A, et al. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009;15:796-800.
11. Fiorino G, Cesarini M, Indriolo A, et al. Mucosal healing in ulcerative colitis: where do we stand Curr Drug Targets. 2011;12:1417-1423.
12. Travis SP, Higgins PD, Orchard T, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011;34:113-124.
13. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13-20.
14. Caprilli R, Latella G, Frieri G. Treatment of inflammatory bowel diseases: to heal the wound or to heal the sick J Crohns Colitis. 2012;6:621-625.
15. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. Br Med J. 1989;298:82-86.
16. Cooney RM, Warren BF, Altman DG, et al. Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials. 2007; 8:17.
17. Riley SA, Mani V, Goodman MJ, et al. Why do patients with ulcerative colitis relapse Gut. 1990;31:179-183.
18. Levenstein S, Prantera C, Varvo V, et al. Development of the Perceived Stress Questionnaire: A new tool for psychosomatic research. J Psychosom Res. 1993;37:19-32.
19. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
20. Fliege H, Rose M, Arck P, et al. The Perceived Stress Questionnaire (PSQ) reconsidered: validation and reference values from different clinical and healthy adult samples. Psychosom Med. 2005;67:78-88.
21. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:385-396.
22. Bitton A, Dobkin PL, Edwardes MD, et al. Predicting relapse in Crohns disease: A biopsychosocial model. Gut. 2008;57:1386-1392.
23. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
24. Herrmann C. International experiences with the Hospital Anxiety and Depression Scale-a review of validation data and clinical results. J Psychosom Res. 1997;42:17-41.
25. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: A bad idea. Stat Med. 2006;25:127-141.
26. Mikocka-Walus AA, Turnbull DA, Moulding NT, et al. Does psychological status influence clinical outcomes in patients with inflammatory bowel disease (IBD) and other chronic gastroenterological diseases: An observational cohort prospective study. Biopsychosoc Med. 2008;2:11.
27. Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: A prospective 18-month follow-up study. Psychosom Med. 2004;66:79-84.
28. Vidal A, Gómez-Gil E, Sans M, et al. The impact of anxiety and depression on relapse in patients with inflammatory bowel disease [Article in Spanish]. Med Clin (Barc). 2009;132:298-302.
29. Levenstein S, Prantera C, Varvo V, et al. Stress and exacerbation in ulcerative colitis: A prospective study of patients enrolled in remission. Am J Gastroenterol. 2000;95:1213-1220.
30. Häuser W, Janke KH, Klump B, et al. Anxiety and depression in patients with inflammatory bowel disease: comparisons with chronic liver disease patients and the general population. Inflamm Bowel Dis. 2011;17:621-632.
31. Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA. 1997;277: 488-494.
32. Bitton A, Sewitch MJ, Peppercorn MA, et al. Psychosocial determinants of relapse in ulcerative colitis: A longitudinal study. Am J Gastroenterol. 2003;98:2203-2208.
33. Haddock CK, Rindskopf D, Shadish WR. Using odds ratios as effect sizes for meta-analysis of dichotomous data: A primer on methods and issues. Psychol Methods. 1998;3:339-353.
34. Bello C, Belaiche J, Louis E, et al. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. J Crohns Colitis. 2011;5:196-202.
35. Park BJ, Lee KJ, Hwang JC, et al. Relapse rates of ulcerative colitis in remission and factors related to relapse [Article in Korean]. Korean J Gastroenterol. 2008;52:21-26.
36. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:53-63.
37. First MB, Spitzer RL, Miriam G, et al. Structured Clinical Interview for DSM-iv Axis I Disorders, Clinician Version (SCID-cv). Washington, DC: American Psychiatric Press, Inc.; 1996.
38. Watson D, Clark LA, Tellegren A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54:1063-1070.
39. Radloff LS. The CES-D scale: A self report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
40. Derogatis LR. SCL-90-R. Symptom checklist-90-R. Administration, Scoring, and Procedures Manual, 3rd ed. Minneapolis, MN: National Computer Systems; 1994.
41. Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis: A multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol. 2000;95:469-473.
42. Langhorst J, Cobelens P, Kavelaars A, et al. Stress-related peripheral neuroendocrine-immune interactions in women with ulcerative colitis. Psychoneuroendocrinology. 2007;32:1086-1096.
43. Boye B, Lundin KE, Jantschek G, et al. INSPIRE study: does stress management improve the course of inflammatory bowel disease and diseasespecific quality of life in distressed patients with ulcerative colitis or Crohns disease A randomized controlled trial. Inflamm Bowel Dis. 2011;17: 1863-1873.
44. Elsenbruch S, Langhorst J, Popkirowa K, et al. Effects of mind-body therapy on quality of life and neuroendocrine and cellular immune functions in patients with ulcerative colitis. Psychother Psychosom. 2005;74: 277-287.
45. Greene BR, Blanchard EB, Wan CK. Long-term monitoring of psychosocial stress and symptomatology in inflammatory bowel disease. Behav Res Ther. 1994;32:217-226.
46. Dave M, Loftus EV Jr. Mucosal healing in inflammatory bowel disease- a true paradigm of success Gastroenterol Hepatol (N Y). 2012;8:29-38.
47. Goodhand JR, Wahed M, Rampton DS. Management of stress in inflammatory bowel disease: A therapeutic option Expert Rev Gastroenterol Hepatol. 2009;3:661-679.